Myeloproliferative Neoplasms News

Bruce Clurman, MD, has been appointed executive vice president and deputy director of Fred Hutchinson Cancer Research Center.

Patients with cancer may have an increased risk for treatment-related and -unrelated injuries in the periods preceding and following their cancer diagnosis, according to the results of a registry study conducted in Sweden.

Patients receiving treatment for myeloproliferative neoplasms often held discordant views regarding disease prognosis, burden and treatment goals compared with their treating physicians, according to data from the MPN Landmark Study.

The American Society for Clinical Pathology has added five recommendations for laboratory treatments and tests that physicians and patients should question, according to a press release from the organization.

Somatic mutations in ASXL1, RUNX1 and TP53 appeared independently associated with poor outcomes and shorter OS in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia, according to study results published in Journal of Clinical Oncology.

A randomized trial assessing whether chlorhexidine-containing catheter securement dressings could significantly reduce the incidence of definite central venous catheter–related bloodstream infections within 14 days of catheter placement failed its primary endpoint, according to result of an open-label, randomized controlled study published in Annals of Oncology.

Extraordinary therapeutic advances, a renewed bipartisan commitment to medical research and the launch of the national cancer moonshot initiative have reinforced the importance of scientific investigation in the fight against cancer.

Vice President Joe Biden outlined a plan to improve the efficiency and transparency of the U.S. clinical research system as part of the national cancer moonshot initiative.

Jeffrey E. Lancet, MD, has been named chair and program leader for the department of malignant hematology at Moffitt Cancer Center.

September is designated as National Blood Cancer Awareness Month.